Navigation Links
New 'bouncer' molecule halts rheumatoid arthritis
Date:9/7/2011

CHICAGO -- Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.


'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related biology news :

1. Unlocking the secret of the bladders bouncers
2. Small molecules shed light on cancer therapies
3. Regrowing blood vessels with a potent molecule
4. UCLA scientists complete first mapping of molecule found in human embryonic stem cells
5. Molecules light up Alzheimers roots
6. Newly discovered molecule essential to resetting body clocks
7. Supramolecules get time to shine
8. Crucial role for molecule in muscle development
9. Researchers decipher protein structure of key molecule in DNA transcription system
10. Treatment approach to human Usher syndrome: Small molecules ignore stop signals
11. Scientists a step closer to understanding natural antifreeze molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
(Date:3/22/2017)... Mass. , March 22, 2017 Good ... that it has eclipsed the 130 million covered lives ... Blue Shield of Texas . With ... the Company continues to enjoy strong payor acceptance based ... its clinical programs and genetic counseling, its industry-leading customer ...
(Date:3/22/2017)... 2017 /PRNewswire/ - FACIT announced a seed stage ... a start-up created by FACIT focused on developing ... combined with non-dilutive capital, achieves a targeted $3.0M ... enables Propellon to accelerate the nomination of a ... and/or entering a strategic partnership for clinical trials ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is ... the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there ... therapeutic antibodies. , To meet this demand, the team at SCIEX has ...
Breaking Biology Technology: